Bushu Pharmaceuticals

Bushu Pharmaceuticals is a contract development and manufacturing organization (CDMO) specializing in pharmaceutical contract manufacturing with over 25 years of experience. The company manufactures solid dosage forms, injectable formulations, high-potency active pharmaceutical ingredients, and packaging solutions for clinical trial drugs, prescription pharmaceuticals, and over-the-counter medicines.

Core Services

Pharmaceutical Manufacturing: Solid dosage forms, injectable formulations, high-potency active pharmaceutical ingredients (HPAPI), and packaging solutions. The company industrializes processes tailored to pharmaceutical company and patient needs, providing products compliant with regulations across multiple countries.

Quality Management & Analysis: Experienced staff in quality assurance and quality control ensure customer requirements are met. The company employs over 350 personnel dedicated to quality management and analytical functions, maintaining positive inspection records from major regulatory authorities including the U.S. FDA.

Supply Chain Management: Includes cold chain management, project management, and special response capabilities for emergency and small-volume production. The company supports global expansion through its "GATEWAY to ASIA" service.

Facilities & Operations

Bushu operates five manufacturing facilities with backup systems across locations: Kawagoe Plant, Misato Plant, Aizu Plant, Kasuga Packaging Center, and Soka Packaging Center (opened November 2023). All facilities are strategically located with good access to major transportation networks while minimizing exposure to natural disasters. The company maintains a dedicated cold chain (refrigerated warehouse) facility.

Quality & Compliance

The company holds GMP certifications from major regulatory regions (US, EU, Japan) and has cleared inspections from all three major regulatory authorities. It receives over 70 audits annually from customers and regulatory bodies, with cumulative audit experience exceeding 500 inspections. Approximately 50% of revenue derives from overseas customers across 56 export countries.